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Abstract
Background: Hypoxia and inflammation have been identified as hallmarks of cancer. A majority of hepatocellular
carcinomas are preceded by hepatitis B- or C-related chronic infections suggesting that liver cancer development is
promoted by an inflammatory microenvironment. The inflammatory cytokine oncostatin M (OSM) was shown to
induce the expression of hypoxia-inducible factor-1α (HIF-1α) under normoxic conditions in hepatocytes and
hepatoma cells. HIF-1α is known to orchestrate the expression of numerous genes, many of which code for metabolic
enzymes that play key roles in the adaptation of cellular metabolism to low oxygen tension.
Results: Here, we show that OSM-induced upregulation of HIF-1α reprograms cellular metabolism in three clones of
the human hepatocyte cell line PH5CH (PH5CH1, PH5CH7, and PH5CH8) towards a hypoxia-like metabolic phenotype
but has no significant effect on cellular metabolism of HepG2 and JHH-4 hepatoma cells. Although we observed only
minor changes in glucose uptake and lactate secretion in PH5CH8 upon OSM treatment, we identified more
pronounced changes in intracellular fluxes based on stable isotope labeling experiments. In particular, glucose
oxidation in the tricarboxylic acid (TCA) cycle is reduced through pyruvate dehydrogenase kinase 1 (PDK1)-mediated
inhibition of the pyruvate dehydrogenase complex, thereby reducing the oxidative TCA cycle flux. As a result of the
impaired mitochondrial glucose and glutamine oxidation, the reductive isocitrate dehydrogenase flux was increased.
Conclusions: We provide evidence that connects the inflammatory mediator OSM to a hypoxia-like metabolic
phenotype. In the human hepatocyte cell line PH5CH, OSM-mediated upregulation of HIF-1α and PDK1 can induce
hypoxia-like metabolic changes, although to a lesser extent than hypoxia itself. Since PDK1 is overexpressed in several
cancers, it might provide a causal link between chronic inflammation and malignant cellular transformation.
Keywords: Oncostatin M, Inflammation, Stable isotope labeling experiments, Hypoxia-inducible factor, Pyruvate
dehydrogenase complex, Pyruvate dehydrogenase kinase
Background
Interleukin 6 (IL6)-type cytokines such as oncostatin M
(OSM) are key players in the regulation of the immune
response, the immune surveillance of tumor cells, and
in the development of cancer [1]. The main functions of
IL6-type cytokines are the induction of the acute phase
response by the liver, the stimulation of liver regeneration
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(by inducing hepatocyte proliferation), and the shift from
the innate to the adaptive immune response [2, 3]. Aber-
rant IL6 signaling is likewise able to induce a state
of chronic inflammation, as observed in many cancer
types and inflammatory diseases. Since hepatocellular
carcinoma (HCC) development can be promoted by an
inflammatory microenvironment, aberrant IL6 signaling
is implicated in the onset of HCC [4, 5]. Elevated IL6 and
OSM serum levels in HCC patients have been reported
to negatively influence disease outcome [6, 7]. A direct
link between IL6 and the onset of HCC was shown in a
study by Naugleret et al., where male IL6 knockout mice
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showed a vastly reduced development of HCC, depict-
ing IL6 as a key mediator in the onset of this cancer
[4]. All IL6-type cytokines signal via a homodimer of
the transmembrane receptor gp130 or a heterodimer of
gp130 with a second receptor chain (e.g., the OSMR or
LIFR for OSM), which bind and activate Janus kinases
(JAKs) upon cytokine binding. In turn, JAKs activate mul-
tiple signaling cascades mainly including STAT3 but also
MEK/Erk and the PI3K/Akt pathways [8]. Recently, we
have shown in non-neoplastic hepatocytes and HCC cells
that STAT3, activated by the IL6-type cytokine OSM,
upregulates HIF-1α expression under normoxic condi-
tions, via a transcriptional mechanism, leading to the
expression of vascular endothelial growth factor (VEGF)
and plasminogen activator inhibitor 1 (PAI) [9]. HIF-1α
regulates the expression of numerous target genes, many
of which code for metabolic enzymes that play key roles
in the adaptation of cellular metabolism to low oxygen
tension [10]. For example, HIF-1α promotes high gly-
colytic rates by upregulating the expression of glucose
transporters and many glycolytic enzymes [11]. In addi-
tion, pyruvate entry into the citric acid cycle is decreased
by HIF-1α-mediated upregulation of pyruvate dehydroge-
nase (PDH) kinase 1 (PDK1), leading to reduced pyruvate
dehydrogenase complex (PDC) activity which results in
reduced mitochondrial respiration and increased conver-
sion of pyruvate to lactate [12–14]. Apart from its function
in glucose metabolism, a strong impact of HIF-1α on glu-
tamine metabolism has been identified. Resulting from
reduced PDC activity, the mitochondrial citrate pool is
drastically depleted. Due to these concentration changes,
the actual free energy change of the isocitrate dehydro-
genase (IDH) reaction will become positive and thus,
reversing the IDH flux towards isocitrate. Consequently,
glutamine-derived α-ketoglutarate is reductively carboxy-
lated to isocitrate by IDH and eventually converted to
citrate [15–17]. Malignant cellular transformation and
proliferation goes hand-in-hand with reprogrammed cel-
lular metabolism [18, 19], mainly characterized by an
increased glucose uptake, a high glycolytic rate, and an
increased conversion of pyruvate to lactate, even under
normoxic conditions (Warburg effect). Most certainly,
this hypoxia-like metabolic phenotype favors increased
proliferation rates, as a high glucose turnover provides
necessary intermediates such as ribose-5-phosphate, ser-
ine, and glycine for macromolecule synthesis. A link
between inflammatory STAT3 activity, HIF-1α, and the
Warburg effect has been described recently. Demaria
and coworkers showed that constitutively active STAT3
induces the Warburg effect in mouse embryonic fibrob-
lasts [20] and renders the cells sensitive for malignant
transformation [21]. Based on our previous finding that
OSM mediates HIF-1α upregulation through increased
mRNA and protein levels in a STAT3-dependent manner,
we aimed to investigate the effects of OSM stimulation on
central carbon metabolism in hepatocytes and hepatoma
cells. Here, we (1) show that OSM induces the expres-
sion of HIF-1α in several HCC cell lines and immortalized
hepatocytes, (2) demonstrate that OSM stimulation leads
to a hypoxia-like metabolic phenotype in three clones of
the immortalized hepatocyte cell line PH5CH, (3) pro-
vide evidence that HIF-1α-mediated PDK1 upregula-
tion is necessary to induce OSM-dependent metabolic
reprogramming in PH5CH cells, and (4) show that OSM-
dependent HIF-1α upregulation is not sufficient to induce
metabolic reprogramming in the HCC cell lines HepG2
and JHH-4.
Methods
Cell culture and reagents
The hepatoma cell lines and the non-neoplastic, SV40
large T antigen-immortalized, hepatocyte lines, PH5CH1,
PH5CH7, and PH5CH8 [22] were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) (AQMe-
dia, Sigma-Aldrich) supplemented with 10% fetal calf
serum (PAA), 100mg/l streptomycin, 60mg/l penicillin,
and 25mM HEPES (Lonza). The SV40 large T antigen-
immortalized human liver epithelial cells (THLE-2) were
cultured in LHC-8 medium supplemented with 70 ng/ml
phosphoethanolamine, 5 ng/ml epidermal growth factor,
10% FBS, 100mg/l streptomycin, and 60mg/l penicillin.
Cells were grown at 37 °C in a water-saturated atmosphere
at 5% CO2. Hypoxia treatment was performed at 37 °C
in a water-saturated atmosphere at 5% CO2 in a hypoxia
chamber (C-Chamber (C-274 & C-374) with a ProOx
C21 Static O2 & CO2 Controller from BioSpherix) at the
indicated oxygen percentage. HIF-1α and HIF-2α screen-
ing experiments were performed in an hypoxia incubator
(Heracell) from Thermo Scientific at 37 °C in a water-
saturated atmosphere at 5% CO2. Human oncostatin
M (227 a.a.) was from PeproTech. For all experiments,
cells were seeded together, stimulated for the indicated
periods of time, and harvested together at the latest
time point.
Western blot analysis and antibodies
Cells were lysed on the dish with ice-cold lysis buffer
containing 30mM Tris/HCl pH 6.7, 5% glycerol, 2.5 %
mercaptoethanol, and 1% SDS. Protein extracts were
separated by SDS-PAGE and analyzed by Western blot-
ting for the following proteins: HIF-1α and STAT3 (BD
Transduction Laboratories), phospho-STAT3, (Cell Sig-
naling), PDH-E1α (pSer232) and PDH-E1α (pSer300)
(Merck Millipore), HIF-2α (Novus Biologicals), PDK1
(Enzo Life Sciences) and α-tubulin (Thermo Fisher Scien-
tific), and PDH-E1α (pSer293) (Abcam). ECL signals were
detected and membranes stripped before re-probing as
previously described [23, 24]. The secondary antibodies
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IRDye 800CW and 680LT (LI-COR Bioscience) were used
for fluorescent Western blot detection with the Odyssey
Infrared imaging system (LI-COR Biosciences) of PDK1.
Quantification of PDK1 protein levels was done using
Image Studio Lite version 4.0 (LI-COR Bioscience). For
the evaluation the HIF-1α protein levels, densitometric
analysis was carried out using the Image-Lab software 4.0
(Bio-Rad Laboratories). The level of the target protein was
normalized to the α-tubulin protein level.
Quantitative PCR procedure
Total RNA was extracted using the NucleoSpin RNA
II kit (Macherey-Nagel) according to the manufacturer’s
instructions. The concentration of isolated RNAwasmea-
sured using a NanoDrop spectrophotometer. Five hun-
dred nanograms of total RNA was reverse-transcribed
with iScript (Bio-Rad Laboratories) in a final volume of
10μl, according to themanufacturer’s instructions. Quan-
titative real-time PCR (qPCR) was carried out on an iQ5
Real-Time PCR detection system (Bio-Rad Laboratories).
The reaction was performed in a total volume of 10μl
containing cDNA corresponding to 5 ng RNA template,
10 pmol of each forward and reverse primer, and 5μl
iTaq Universal SYBR Green Supermix (Bio-Rad Labora-
tories). Thermal cycling conditions for all qPCR assays
consisted of an initial enzyme activation step at 95 °C for
15min, followed by 40 cycles of denaturation at 95 °C, and
annealing and elongation at 60 °C for 30 s. The house-
keeping genes Cyclo A, HPRT, EEF1a, YWHAZ, and the
target genes were assayed in parallel for each sample. All
samples were run in triplicates. Gene-specific primers
for Cyclo A, HPRT, EEF1a, YWHAZ, HIF-1α, HIF-
2α, PDK1, and PDP2 were purchased from Eurogentec
(Belgium). The geometric mean of three housekeeping
genes was calculated, and a normalization factor for
each sample was generated using geNorm (VBA add-in
for Microsoft Excel). The normalization factor was used
to calculate the relative amount of each target in each
sample. Each sample was normalized to the untreated
control.
Total RNA extraction in HIF-1α silencing experiments
was performed using the RNeasy mini kit (QIAGEN)
according to the manufacturer’s instructions. Six hun-
dred nanograms of total RNA was reverse-transcribed
using SuperScript III reverse transcriptase (Invitrogen)
in a final volume of 20μl according to manufacturer’s
recommendations. qPCR was performed on a LightCy-
cler 480 (Roche) in a total volume of 20μl containing
cDNA corresponding to 6 ng RNA template, 5 pmol of
each forward and reverse primer, and 10μl iTaq Univer-
sal SYBRGreen Supermix (Bio-Rad Laboratories). Cycling
conditions were identical to those described earlier. Tar-
get gene expression was normalized to the housekeeping
gene L27.
siRNA-mediated silencing of HIF-1α and PDK1
For the siRNA-mediated HIF-1α knockdown, 3μl of
Lipofectamine RNAiMAX (Invitrogen) was diluted in
150μl 1× Opti-MEM I (Gibco by Life Technologies) and
1μl siRNA was added. The final concentration of non-
targeting (Dharmacon, Inc.) and HIF-1α siRNA (Santa
Cruz) was 15 nM. For the siRNA-mediated PDK1 knock-
down, 2.5μl of Lipofectamine RNAiMAX was diluted
in 200μl 1× Opti-MEM I and 1μl siRNA (Dharmacon,
Inc.) was added. The final concentration of non-targeting
and PDK1 siRNA was 20 nM. The Lipofectamine/siRNA
mix was incubated for 20min at room temperature,
then transferred into a 12-well plate and incubated for
another 5min. PH5CH1, PH5CH7, and PH5CH8 cells
were directly seeded onto the transfection mix. After 6 h,
the medium was changed to complete culture media and
cells were grown overnight.
Stable isotope labeling experiments
Cells were seeded and grown overnight. Complete
cell culture medium was then replaced with labeling
medium. For isotope labeling experiments using uni-
formly labeled glucose, cells were cultured in DMEM sup-
plemented with 10% dialyzed FBS (Invitrogen), 25mM
[13C6]glucose (Cambridge Isotope Laboratories), and
4mM glutamine (Sigma-Aldrich). For isotope labeling
experiments using uniformly labeled glutamine, cells
were grown in DMEM supplemented with 10% dialyzed
FBS (Invitrogen), 25mM glucose (Sigma-Aldrich), and
4mM [13C5] glutamine (Cambridge Isotope Laborato-
ries). Cells were stimulated with 50 ng/ml OSM (Pepro-
Tech) and grown for 36 h under normoxia or hypoxia
(1% O2) (Jacomex) at 37 °C, 5% CO2 and humidified
atmosphere. Metabolites were extracted as described
previously [25].
Extraction of extracellular metabolites
Extracellular metabolites from medium samples
were extracted using ice-cold extraction fluid (8:1
methanol/water) containing the internal standard
[13C5]ribitol (Omicron Biochemicals, Inc.) at a concen-
tration of 10μg/ml. Twenty microliters of the medium
was added to 180μl ice-cold extraction fluid, vortexed for
10 s, and centrifuged at maximum speed for 5min at 4 °C.
Fifty microliters of the medium extracts was transferred
to GC-MS glass vials and evaporated under vacuum to
dryness at −4 °C using the CentriVap Concentrator.
GC-MS analysis
Metabolite derivatization was performed using a Gerstel
MPS. Dried polar metabolites were dissolved in 15μl
of 2% methoxyamine hydrochloride in pyridine at
40 °C under shaking. After 60min, an equal volume of
MTBSTFA was added and held for 30min at 40 °C under
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continuous shaking. One microliter sample was injected
into an SSL injector at 270 °C in splitless mode. GC-MS
analysis was performed using an Agilent 7890A GC
equipped with a 30-m DB-35MS + 5-m Duraguard capil-
lary column. Helium was used as carrier gas at a flow rate
of 1ml/min. The GC oven temperature was held at 100 °C
for 2min and increased to 300 °C at 10 °C/min. After
3min, the temperature was increased to 325 °C. The GC
was connected to an Agilent 5975C inert XLMSD, operat-
ing under electron ionization at 70 eV. TheMS source was
held at 230 °C and the quadrupole at 150 °C. The detec-
tor was operated in single ion mode (see Additional file 1:
Table S1 for details). The total run time of one sample was
25.00min.
Mass isotopomer distribution analysis
All GC-MS chromatograms were processed using
MetaboliteDetector [26]. Chemical formulas for mass iso-
topomer distribution (MID) determination (Additional
file 1: Table S1) were taken from [27]. Weighted carbon





Mi ∗ i, where n is the number of carbons of the
molecule of interest andMi the ith mass isotopomer.
Statistical analysis
Error bars represent the standard deviation unless other-
wise noted. Statistical significance was determined using
two-tailed Student’s t test. One asterisk denotes P < 0.05,
two asterisks denote P < 0.01, and three asterisks denote
P < 0.001.
Results
Oncostatin Mmediates induction of HIF-1α in hepatocytes
and hepatoma cells
Based on our previous observation that oncostatin M
(OSM) treatment induces HIF-1α expression in hepato-
cytes under normoxia, we first investigated whether the
OSM-mediated upregulation of HIF-1α is a general effect
for hepatocytes and hepatoma cells [9]. Therefore, we
evaluated HIF-1α protein levels after OSM stimulation
and hypoxia in 11 HCC and two non-neoplastic hepato-
cyte cell lines 8 and 36 h after treatment (Additional file 2:
Figure S1). After 8 h, we detected increased HIF-1α pro-
tein levels following OSM treatment in eight out of 11
cell lines, whereas after 36 h only five cell lines showed an
increase in HIF-1α protein levels (Fig. 1a). Compared to
OSM, the effect of hypoxia on HIF-1α protein levels was
generally more pronounced (Additional file 2: Figure S1).
In ten cell lines, we detected hypoxia-mediated HIF-1α
protein induction after 8 h and in nine cell lines after 36 h
(Fig. 1a).
We selected three of these cell lines for an in-depth
study of OSM-induced effects on cellular metabolism.
HepG2 and JHH-4 are hepatocellular carcinoma cell lines,
whereas PH5CH8 cells are immortalized hepatocytes.
In PH5CH8 and HepG2 cells, we observed that OSM
upregulates HIF-1α mRNA expression over the entire
time course, while we measured only a weak induction
of HIF-1α mRNA expression in JHH-4 cells (Fig. 1b).
In non-neoplastic PH5CH8 cells, we observed con-
tinuous OSM-dependent induction of HIF-1α protein
levels, comparable to those observed under hypoxia
(Fig. 1c, d). In HepG2 cells, we detected a transient
induction of HIF-1α protein levels, peaking around
12 h post-OSM treatment (Fig. 1c, d). Correlating with
the weak induction on HIF-1α mRNA, we did not
observed an increase in HIF-1α levels in JHH-4 cells
(Fig. 1b, c).
OSM stimulation reduces glucose oxidation via PDC
inhibition under normoxia in non-transformedhepatocytes
Based on the observed OSM-induced upregulation of
HIF-1α under normoxia, we hypothesized that this would
induce a pseudo-hypoxic metabolic phenotype. To inves-
tigate the effect of OSM stimulation on central car-
bon metabolism, we performed stable isotope labeling
experiments using [13C6]glucose and [13C5]glutamine and
quantified the isotopic enrichment in form of MIDs.
Therefore, we cultured PH5CH8 cells under normoxia
(18.6% O2), hypoxia (1% O2) either with or without
50 ng/ml OSM. We observed a significant decrease (P <
0.001) in glucose carbon contribution to citrate in OSM-
stimulated cells under normoxia as compared to the
control (Fig. 2a), although glucose uptake was slightly
increased (Additional file 3: Figure S2A). In line with a
reduced glucose carbon contribution to the TCA cycle,
we observed increased lactate secretion (Additional file 3:
Figure S2A). We next investigated whether the decreased
glucose contribution is a result of reduced anaplerosis via
pyruvate carboxylase (PC) or reduced PDC activity. Using
[13C6]glucose as a tracer, the two pathways can be dis-
tinguished by analyzing the M2 and M3 isotopologues of
citrate. Briefly, PDC activity generates [13C2]acetyl-CoA
from which M2 citrate is produced, whereas PC activity
yields [13C3]oxaloacetate leading to M3 citrate (Fig. 2b).
M5 isotopologues of citrate reflect the combined carbon
contribution of PC and PDC to citrate. To exclude bias
from the overall enrichment, we normalized the abun-
dance of the M2, M3, and M5 isotopologues of citrate to
the abundance of the M3 isotopologue of lactate. While
there was no difference in M3 and M5 isotopologues
(data not shown), OSM-stimulated cells exhibited a sig-
nificantly (P = 0.003) reduced M2-citrate-to-M3-lactate
ratio under normoxic conditions, pointing to reduced glu-
cose catabolism via PDC (Fig. 2c) and thus a reduced
oxidative TCA cycle flux. Reduced M2 isotopologues
propagated to all analyzed downstreammetabolites in the
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Fig. 1 OSM induces HIF expression in hepatoma cells and hepatocytes under normoxic conditions. a Eleven HCC cell lines and two non-neoplastic
hepatocyte cell lines (THLE-2, PH5CH8) were screened for the induction of HIF-1α protein levels by OSM treatment or hypoxia (green indicates
protein induction, red no HIF-1α protein induction). b–d HepG2, JHH-4, and PH5CH8 cells were selected for further analysis and treated with
50 ng/ml OSM, hypoxia (1% O2), or a combinatorial treatment for the indicated periods of time. b Quantitative RT-PCR of HIF-1α. The fold change
was calculated relative to the untreated control. Error bars represent the standard deviation of three biological replicates. cWestern blot analysis of
HIF-1α. α-Tubulin was used as a loading control, and one representative blot for α-tubulin is shown. S. Exp. indicates short exposure, L. Exp. long
exposure. d Quantification of HIF-1α protein levels in HepG2 and PH5CH8 cells after the different treatments. Statistical significance was determined
in comparison to the untreated control. *P <= 0.05, **P <= 0.01, and ***P <= 0.001
TCA cycle (Additional file 4: Table S2). Although HIF-1α
protein levels upon OSM treatment were comparable to
those under hypoxic conditions (Fig. 1d), we observed a
much stronger effect on cellular metabolism induced by
hypoxia. Specifically, PDC activity and consequently glu-
cose carbon contribution to citrate were almost reduced
to zero (Fig. 2a, c). OSM treatment did not further impact
glucose oxidation under hypoxia (Fig. 2a, c).
Since PDC links glycolysis and TCA cycle, it is
tightly regulated. Its activity is mainly controlled through
reversible phosphorylation of the PDH-E1α subunit.
An inhibition of the complex is mediated by its
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Fig. 2 Effect of OSM on central carbon metabolism of PH5CH8 under normoxia and hypoxia. a–f PH5CH8 cells were treated with 50 ng/ml OSM,
hypoxia (1% O2), or a combinatorial treatment, and metabolites were extracted after 36 h. a Relative glutamine and glucose carbon contribution to
citrate. b Carbon atom transitions of pyruvate carboxylase (PC) and pyruvate dehydrogenase complex (PDC). c PDC activity determined by the ratio
of M2 isotopologues of citrate to M3 isotopologues of lactate, from [13C6]glucose. d Atom transitions for reductive carboxylation and oxidative
decarboxylation of α-ketoglutarate. e Oxidative glutamine contribution to citrate, determined by the ratio of M4 isotopologues of citrate to M5
isotopologues of glutamate, from [13C5]glutamine. f Reductive glutamine contribution to citrate, determined by the ratio of M5 isotopologues of
citrate to M5 isotopologues of glutamate, from [13C5]glutamine. g–j PH5CH8 cells were treated with different concentrations of OSM. Metabolites
and proteins were extracted after 36 h. g HIF-1α protein levels in PH5CH8 cells after treatment with the indicated OSM concentrations. h PDC
activity determined by the ratio of M2 isotopologues of citrate to M3 isotopologues of lactate, from [13C6]glucose. i Oxidative glutamine
contribution to citrate, determined by the ratio of M4 isotopologues of citrate to M5 isotopologues of glutamate, from [13C5]glutamine. j Reductive
glutamine contribution to citrate, determined by the ratio of M5 isotopologues of citrate to M5 isotopologues of glutamate, from [13C5]glutamine.
All error bars indicate the standard deviation. All p values and error bars are calculated from at least two independent replicates (n >= 2). Statistical
significance was determined in comparison to the untreated control. *P <= 0.05, **P <= 0.01, and ***P <= 0.001
phosphorylation via pyruvate dehydrogenase kinases
(PDK1-4), whereas a dephosphorylation through pyru-
vate dehydrogenase phosphatases (PDP1-2) leads to an
increase in PDC activity. PDK1 is a direct HIF-1α tar-
get gene, and its upregulation has been implicated in
the metabolic switch induced by HIF-1α [13]. For that
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reason, we determined the effect of OSM treatment on
PDK1 and PDP2 mRNA levels. Furthermore, we analyzed
the degree of phosphorylation of all three serine phos-
phorylation sites of the PDH-E1α subunit by Western
blot. We observed an increase in the expression of PDK1
following OSM treatment, which was, however, weaker
compared to hypoxia and hypoxia in combination with
OSM treatment (Fig. 3a–c). The transcription of PDP2
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Fig. 3 PDK1 levels are increased upon OSM stimulation under
normoxia in PH5CH8 non-neoplastic hepatocytes. PH5CH8 cells were
treated with OSM (50 ng/ml), hypoxia (1% O2), or a combinatorial
treatment for the indicated periods of time. a Quantitative RT-PCR of
PDK1 and PDP2 mRNA. The fold change was calculated relative to the
untreated control. bWestern blot analysis for all three PDH
phosphorylation sites (S232, S293, S300) and PDK1. α-Tubulin was
used as a loading control, and one representative α-tubulin blot is
shown. c Quantification of PDK1 protein levels, shown as percentage
of the untreated control. All error bars indicate the standard deviation
from three biological replicates. Statistical significance was
determined in comparison to the untreated control. *P <= 0.05,
**P <= 0.01, and ***P <= 0.001
remained unaffected byOSM (Fig. 3a). Moreover, hypoxia
led to increased phosphorylation levels of the PDH-E1α
subunit at all three serine residues, whereas the results
for OSM were not as unambiguous. We did not observe
a clear effect on any of the three serine residues after
OSM treatment (Fig. 3b). Hypoxia led to higher PDK1
protein levels than OSM, correlating with the weaker
effect of OSM on PDC activity. Collectively, these data
indicate that OSM treatment reduces PDC activity under
normoxia in PH5CH8 cells but to a weaker extent than
hypoxia.
OSM stimulation increases reductive carboxylation of
α-ketoglutarate
Because of the observed reduced glucose oxidation in
the TCA cycle via PDC inhibition, we next sought to
investigate whether this reduction is compensated by an
increased glutamine contribution. To quantify the rela-
tive contribution of glutamine to the TCA cycle, we cul-
tured PH5CH8 cells in the presence of [13C5]glutamine.
We observed a modest increase of glutamine-derived
carbon in citrate under OSM-stimulation (Fig. 2a). Using
[13C5]glutamine as a tracer, the M4 isotopologue of cit-
rate results from a condensation of [13C4]oxaloacetate
and unlabeled acetyl-CoA (Fig. 2d), thereby providing
a readout of relative glutamine oxidation in the TCA
cycle. Although the fractional carbon contribution of glu-
tamine to citrate was increased, we observed a decreased
relative M4 isotopologue abundance when stimulating
PH5CH8 cells with OSM under normoxic conditions
(Fig. 2e), pointing to a decreased glutamine oxidation in
the TCA cycle upon OSM stimulation. This result sug-
gests that the glucose-derived acetyl-CoA pool is not fully
replenished by an alternative acetyl-CoA source such as
increased fatty acid oxidation or degradation of branched
chain amino acids. We also observed reduced M4 iso-
topologues in downstream metabolites including malate,
fumarate, and aspartate (Additional file 5: Table S3). Alter-
natively, citrate can be generated through reductive car-
boxylation of α-ketoglutarate via IDH, eventually yielding
M5 citrate (Fig. 2d). Reductive carboxylation was signif-
icantly increased (P < 0.001) in OSM-stimulated cells
compared to the control, as indicated by an increased
M5 isotopologue abundance (Fig. 2f). In agreement with
an increased relative reductive IDH flux, we observed
increased α-ketoglutarate levels together with decreased
citrate levels in OSM-stimulated cells (see Additional
file 3: Figure S2B). In line with the higher reduction
of PDC activity under hypoxia (Fig. 2c), we observed
a much stronger suppression of glutamine oxidation
(Fig. 2e) and a higher induction of reductive IDH activity
under hypoxia (Fig. 2f). However, OSM treatment did not
have any effect on glutamine metabolism under hypoxia
(Fig. 2e, f).
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OSM stimulation reduces glucose oxidation and increases
reductive glutamine metabolism in a
concentration-dependent manner
To investigate whether OSM affects cellular metabolism
in a dose-dependent manner, we cultured PH5CH8 cells
with 10, 25, and 50 ng/ml OSM. We found that OSM-
mediated HIF-1α protein induction steadily increased
with the OSM concentration (Fig. 2g). While we observed
the strongest effect on cellular metabolism with 50 ng/ml
OSM, we observed a reduction of glucose and glutamine
oxidation as well as increase of reductive glutamine
metabolism already with 10 ng/ml OSM (Fig. 2h–j).
HIF-1α-mediated PDK1 upregulation is critical for
OSM-inducedmetabolic reprogramming in PH5CH8 cells
To validate the hypothesis that OSM-induced metabolic
reprogramming is caused by increased HIF-1α activity,
we silenced HIF-1α expression in PH5CH8 using siRNA
(Fig. 4f). A scrambled siRNA was included as a con-
trol to exclude secondary effects of the transfection.
Silencing of HIF-1α almost completely prevented the
metabolic reprogramming induced by OSM. Specifically,
glucose-derived carbon in citrate increased under nor-
moxia and hypoxia (Fig. 4a) and was comparable to levels
of untreated cells (Fig. 2a). Glutamine carbon contribution
to citrate decreased in HIF-1α-silenced cells under nor-
moxia and hypoxia (Fig. 4b). Moreover, silencing of HIF-
1α decreased PDK1 expression (Fig. 4e), increased PDC
activity (Fig. 4c), and decreased reductive carboxylation
(Fig. 4d). Overall, these data suggests that HIF-1α is criti-
cal for OSM-dependent metabolic phenotype observed in
PH5CH8 cells.
Based on the observation that PDK1 expression is
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Fig. 4Metabolic effects of HIF-1α silencing on the OSM-induced metabolic phenotype. a Relative glucose contribution to citrate. b Relative
glutamine contribution to citrate. c PDH activity determined by the ratio of M2 isotopologues of citrate to M3 isotopologues of lactate, from
[13C6]glucose. d Reductive glutamine contribution to citrate, determined by the ratio of M5 isotopologues of citrate to M5 isotopologues of
glutamate, from [13C5]glutamine. e PDK1 gene expression. f HIF-1α gene expression. Fold changes for qPCRs were calculated relative to the gene
expression in control samples under normoxia or hypoxia, respectively. All error bars indicate the standard deviation. All p values and error bars are
calculated from at least two independent replicates (n >= 2). Metabolites were extracted after 36 h of indicated treatment. Statistical significance
was determined in comparison to the untreated control. *P <= 0.05, **P <= 0.01, and ***P <= 0.001
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manner, we silenced PDK1 in PH5CH8 cells (Fig. 5a, b).
As a consequence of suppressed PDK1 expression,
previously observed OSM-mediated metabolic changes
were attenuated. Both the OSM-induced changes in PDC
activity and reductive carboxylation of α-ketoglutarate
were impaired when PDK1 was silenced (Fig. 5c, d).
Under hypoxic conditions, we detected a pronounced
increase in PDC activity and drastically reduced reduc-
tive glutaminemetabolism (Fig. 5c, d). Taken together, our
results show that the OSM-induced metabolic phenotype
in PH5CH8 cells is mediated by HIF-1α-dependent PDK1
upregulation.
OSM induces PDK1-dependent metabolic reprogramming
in other PH5CH clones
In order to show that OSM-mediated metabolic repro-
gramming is not a unique feature in PH5CH8 cells,
we aimed to validate our main findings in two other
PH5CH clones PH5CH1 and PH5CH7. In line with
our findings in PH5CH8, we detected continuous
OSM-dependent HIF-1α and PDK1 mRNA upregulation
and protein induction (Additional file 6: Figure S3A and
S3D), while PDP2 mRNA levels were downregulated.
HIF-1α protein levels were comparable to those found
under hypoxia (Additional file 6: Figure S3B and S3E).
Furthermore, OSM treatment reduced the entry of
glucose-derived carbon into the TCA cycle and induced
reductive glutamine metabolism (Fig. 5g, h). As already
observed in PH5CH8, silencing of PDK1 attenuated
the OSM-mediated metabolic changes in PH5CH1 and
PH5CH7 cells (Fig. 5g, h). Taken together, these results
confirm that PDK1 is required to induce a hypoxia-





















































































































































































































































































































Fig. 5Metabolic effects of PDK1 silencing on the OSM-induced metabolic phenotype in three PH5CH hepatocyte clones. a PDK1 mRNA expression
in PH5CH8 cells. Fold changes were calculated relative to PDK1 expression in control samples under normoxia or hypoxia, respectively. b PDK1
protein expression in PH5CH8 cells. c PDH activity in PH5CH8 cells determined by the ratio of M2 isotopologues of citrate to M3 isotopologues of
lactate, from [13C6]glucose. d Reductive glutamine contribution to citrate in PH5CH8 immortalized hepatocytes, determined by the ratio of M5
isotopologues of citrate to M5 isotopologues of glutamate, from [13C5]glutamine. e PDK1 mRNA and f protein levels in PH5CH1 and PH5CH7 cells
under normoxia. g PDH activity under normoxia in PH5CH1 and PH5CH7 cells determined by the ratio of M2 isotopologues of citrate to M3
isotopologues of lactate, from [13C6]glucose. h Reductive glutamine contribution to citrate under normoxia in PH5CH1 and PH5CH7 immortalized
hepatocytes, determined by the ratio of M5 isotopologues of citrate to M5 isotopologues of glutamate, from [13C5]glutamine. Metabolites were
extracted after 36 h of indicated treatment. All error bars indicate the standard deviation. All p values and error bars are calculated from at least three
independent replicates (n >= 3). Statistical significance was determined in comparison to the untreated control. *P <= 0.05, **P <= 0.01, and
***P <= 0.001
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OSM-dependent HIF-1α upregulation is not sufficient to
induce a hypoxia-like metabolic phenotype in two
hepatoma cell lines
Since aberrant IL6 signaling is implicated in the onset
of HCC development, we next sought to investigate the
effect of OSM on the two HCC cell lines HepG2 and
JHH-4. Although HIF-1α mRNAwas increased in HepG2
(Fig. 1b) and HIF-1α protein was transiently induced by
OSM treatment (Fig. 1c, d), we did not observe changes
in glucose and glutamine metabolism after 36 h of OSM
stimulation (Fig. 6a–c). To verify that OSM has indeed
no metabolic effect, we profiled cellular metabolism of
HepG2 at 6 and 15 h post-OSM stimulation (Additional
file 7: Figure S4). In line with HIF-1α mRNA and protein
expression levels in JHH-4 cells (Fig. 1b, c), we did not
observe OSM-mediated metabolic changes (Fig. 6a–c).
Under hypoxic conditions, however, glucose oxidation
was suppressed, while glutamine carbon contribution was
highly increased in both cell lines (Fig. 6a). In line with
these data, we observed decreased PDC activity under
hypoxia but no effect of OSM treatment under normoxia
(Fig. 6b). We observed the same for reductive carboxy-
lation of α-ketoglutarate, which was increased under
hypoxia but not significantly affected by OSM treatment
under normoxia (Fig. 6c). In agreement with the MID
data, we did not observe an induction of PDK1 (Fig. 7a,
c, d, f). Concordantly, phosphorylation at any of the three
serine residues of PDH was not induced after OSM stim-
ulation under normoxia in these two cell lines (Fig. 7b, e).
Taken together, these data show that, in HepG2 and JHH-
4, OSM did not induce the metabolic changes observed
in the three clones of the human hepatocyte cell line
PH5CH.
Discussion
Along with others, we reported that transcription of HIF-
1α, one of the master regulators of the cellular response
to hypoxia, is upregulated through IL6-type cytokine
(e.g., IL6 and OSM) signaling or other activators of the
JAK/STAT3 signaling pathway [9, 20]. Because HIF-1α is
heavily induced by hypoxia, we hypothesized that OSM
induces a hypoxia-like metabolic phenotype under nor-
moxic conditions. In this study, we provide insights in
how OSM affects transcriptional regulation of central
metabolism and how the transcriptional changes prop-
agate to redirect intracellular metabolic fluxes. First,
we demonstrated that OSM treatment under normoxia
leads to an upregulation of PDK1 in three clones of
the immortalized hepatocyte cell line PH5CH. Increased
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Fig. 6 Effect of OSM treatment on central carbon metabolism of HepG2 and JHH-4. a Relative carbon contribution to citrate. b PDC activity
determined by the ratio of M2 isotopologues of citrate to M3 isotopologues of lactate, from [13C6]glucose. c Reductive glutamine contribution to
citrate, determined by the ratio of M5 isotopologues of citrate to M5 isotopologues of glutamate, from [13C5]glutamine. All error bars indicate the
standard deviation. All error bars are calculated from at least two independent replicates (n >= 2). Metabolites were extracted after 36 h of
indicated treatment
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Fig. 7 OSM does not influence PDK1 levels in the two HCC cell lines. Cells were treated with OSM (50 ng/ml), hypoxia 1% O2, a combinatorial
treatment for the given time points. a, d qRT-PCR of PDK1 and PDP2 after the indicated period of time and treatment, mRNA from three biological
replicates in HepG2 (a) and JHH-4 (d) cells. Fold change was calculated to the untreated control. b, eWestern blot analysis of all three PDH
phosphorylation sites (S232, S293, S300) and PDK1 in HepG2 (b) and JHH-4 (d) cells. α-Tubulin was used as a loading control and one representative
α-tubulin blot is shown. c, f PDK1 protein levels in HepG2 (c) and JHH-4 (f) cells after the indicated period of time and treatment, shown as
percentage of the untreated control. All error bars indicate the standard deviation calculated from three biological replicates. Statistical significance
was determined in comparison to the untreated control. *P <= 0.05, **P <= 0.01, and ***P <= 0.001
levels (Fig. 3a, c; Additional file 6: Figure S3C), which cor-
related with reduced PDC activity (Fig. 2c, Fig. 5g) and
therefore reduced glucose oxidation in the TCA cycle.
Reduced glucose-derived acetyl-CoA was not compen-
sated by an alternative acetyl-CoA source such as fatty
acid oxidation or degradation of branched chain amino
acids, leading to reduced glutamine oxidation (Fig. 2e,
Fig. 5h). As a result of the reduced glucose and glutamine
oxidation, the intracellular citrate levels decreased, trig-
gering reductive α-ketoglutarate carboxylation by mass
action [15, 28]. This is in line with a previous study by
Gameiro et al., showing that reductive carboxylation is
triggered by a deficient mitochondrial pyruvate oxidation
[16]. These results indicate that PDK1 plays an important
role in the OSM-induced metabolic phenotype. Together,
our current work shows that OSM treatment under nor-
moxic conditions induces an intermediate metabolic phe-
notype between hypoxia (1% O2) and normoxia (18.6%
O2) in PH5CH8 cells. This metabolic phenotype can sup-
port high proliferation rates. Although OSM was impli-
cated in increased hepatocyte proliferation in vivo after
partial hepatectomy (Nakamura et al. 2004), we did not
observe an effect on the growth rate of PH5CH8 cells (data
not shown).
Second, to confirm our hypothesis that the OSM-
induced metabolic changes are HIF-1α-dependent, we
demonstrated that silencing of HIF-1α almost completely
attenuated the OSM-dependent metabolic effects under
normoxia, showing that HIF-1α expression is critical for
OSM-dependent metabolic reprogramming. This depen-
dency on HIF-1α activity explains why although OSM
leads to increased HIF-1α protein levels under hypoxia, it
does not have any additional effect, as with 1% oxygen,
the amount of transcriptionally active HIF-1α cannot be
further induced through OSM. Interestingly, silencing of
HIF-1α under hypoxia increased glucose-derived pyru-
vate oxidation, suggesting that glucose-derived acetyl-
CoA and thus downregulated PDC activity is the limiting
factor and not only reduced O2 availability for respiration
under hypoxia.
Third, we identified PDK1 as a critical HIF-1α down-
stream regulator of the OSM-induced metabolic changes.
PDK1 knockdown, however, did not fully abolish OSM-
mediated effects on intracellular metabolic fluxes (Fig. 5c,
d, g, h). Possibly, our siRNA-mediated PDK1 silencing
was not sufficiently strong to fully abolish PDK1 activ-
ity, although PDK1 protein levels were not detectable by
Western blot anymore (Fig. 5b, f). Furthermore, it cannot
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be excluded that yet another regulator is involved in the
mediation of OSM-dependent metabolic reprogramming.
Finally, we demonstrated that in HepG2 and JHH-4,
OSM did not induce the metabolic changes we observed
in the PH5CH clones (Figs. 6 and 7). This is potentially
explained by the fact that OSM did not induce HIF-1α
in JHH-4 or solely in a transient way in HepG2. Even
in the PH5CH clones, where OSM-induced HIF-1α pro-
tein levels are similar to those induced by hypoxia, the
impact on PDK1 expression was less pronounced. In addi-
tion, the metabolic effect observed upon OSM in the
PH5CH clones was lower compared to the metabolic
changes induced by hypoxia. Taken together, these data
raise the hypothesis that OSM-induced HIF-1α is not
as potent in activating HIF downstream responses as
hypoxic HIF. This might be due to the fact that HIF-1α
is post-translationally regulated by the following mecha-
nisms: (1) Under normoxia, OSM-induced HIF-1α might
still be hydroxylated by PHDs on proline and asparagine
residues. Hence, VHL binds HIF-1α and tags it for
proteasomal degradation leading to a faster degrada-
tion as compared to stabilized HIF-1α under hypoxia.
VHL binding complexes might also interfere with HIF-
mediated transcription or lead to a reduced binding time
of HIF on promotors. In addition, factor-inhibiting HIF
(FIH)-mediated asparagine hydroxylation in the trans-
activation domain of HIF-1α prevents cofactor binding
(CEBP) and might thereby reduce effective transcription
[29, 30]. (2) HIF-1α might be modified by other post-
translational modifications upon hypoxia compared to
OSM-induced HIF-1α under normoxia and thus altering
its function. In addition to hydroxylation, HIF1α is known
to undergo acetylation, phosphorylation, S-nitrosylation,
and SUMOylation [31]. (3) Known cofactors of HIF-1α
(e.g., TAZ) found under hypoxia might not be present in
normoxic conditions [32].
We have previously shown, however, that at least the
HIF-1α target genes VEGF and PAI as well as HIF-1α-
dependent reporter gene constructs under the control of
the VEGF or the PAI promoter or of HRE elements are
upregulated upon OSM stimulation [9]. Hence, OSM-
induced HIF-1α can be an active transcription factor in
HepG2 cells. However, it remains unclear why we were
not able to detect HIF-1α-induced metabolic changes in
HepG2 cells in this study. VEGF was discussed to be
not only a HIF-1α but also a STAT3 target gene [33].
Therefore, it is possible that VEGF and PAI are regulated
by both transcription factors. In contrast to HIF, STAT3
might be able to recruit cofactors under normoxia that
HIF cannot, as it remains hydroxylated at asparagine. For
many metabolic genes (which are not STAT3 responsive
or mainly rely on HIF-1α for transcriptional regulation),
asparagine hydroxylation might prevent HIF from being
fully active.
Collectively, our data shows that HIF-1α is necessary
but not sufficient to induce OSM-dependent metabolic
reprogramming of hepatic cells.
Conclusions
Hypoxia and inflammation have been recognized as con-
ditions favoring carcinogenesis [18]. Both microenviron-
ments induce profound changes in cellular metabolism
towards a more glycolytic phenotype [34], and it is
assumed that high rates of glycolysis provide a selec-
tive growth advantage that promotes tumor progression
[35]. However, it is still debated whether these metabolic
changes are a consequence or a cause of carcinogene-
sis [35]. The OSM-induced metabolic changes described
in this study would support increased proliferation rates
and are similar to the metabolic adaptations described
in tumors [19]. Hence, OSM-dependent metabolic repro-
gramming might serve as a first hit in carcinogenesis,
which connects chronic infections to increased risks of
tumor development. On the other hand, our experiments
only applied acute treatments (50 ng/ml OSM, 18.6% O2,
and 1% O2) and certainly do not reflect chronic condi-
tions as encountered in a tumor. It will be interesting to
investigate whether long-term activity of the JAK/STAT3
pathway affects hepatocyte/hepatoma cell metabolism in
a different way.
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